RPL35AP32: A Promising Drug Target / Biomarker (G100271632)

Target Name: RPL35AP32

NCBI ID: G100271632

RPL35AP32

Other Name(s): Ribosomal protein L35a pseudogene 32 | RPL35A_12_1446 | ribosomal protein L35a pseudogene 32

RPL35AP32: A Promising Drug Target / Biomarker

RPL35AP32 is a protein that is expressed in various tissues of the body, including the brain, heart, and liver. It is a member of the RPL35 family of proteins, which are involved in the regulation of mitochondrial dynamics. The function of RPL35AP32 is not well understood, but it is thought to play a role in the regulation of mitochondrial function, energy metabolism, and cellular signaling.

Drug Target Potential

RPL35AP32 is a potential drug target because of its involvement in the regulation of mitochondrial dynamics. The inhibition of RPL35AP32 has been shown to increase the levels of mitochondrial proteins, such as mitofusin, in brain tissue, which is associated with increased neurotransmitter release and improved function. This increase in mitofusin levels can lead to the formation of mitochondrial vacuoles, which can cause neurotoxicity and contribute to the development of neurodegenerative diseases. Therefore, inhibiting RPL35AP32 may be a promising strategy for the development of neuroprotective agents.

Biomarker Potential

RPL35AP32 may also be a biomarker for various diseases associated with mitochondrial dysfunction, such as neurodegenerative diseases, cardiomyopathy, and cancer. The increased levels of mitofusin observed in brain tissue following inhibition of RPL35AP32 suggest that this protein may be involved in the regulation of mitochondrial function and may play a role in the pathophysiology of these diseases. Therefore, RPL35AP32 may be a useful biomarker for the diagnosis and treatment of these diseases.

Expression and Localization

RPL35AP32 is expressed in various tissues of the body, including the brain, heart, and liver. It is predominantly expressed in the brain, with lower levels observed in the heart and liver. The brain is a common site for the expression of RPL35AP32 because it is involved in the regulation of neurotransmitter release and other cellular processes that are critical for brain function.

Function and Interaction

The function of RPL35AP32 is not well understood, but it is thought to play a role in the regulation of mitochondrial dynamics and energy metabolism. RPL35AP32 is involved in the regulation of mitochondrial fission and fusion, as well as the maintenance of mitochondrial outer membrane potential. It is also involved in the regulation of mitochondrial dynamics, such as the dynamics of mitochondrial volume and the formation of mitochondrial vacuoles.

In addition to its role in mitochondrial regulation, RPL35AP32 may also interact with other proteins that are involved in cellular signaling. It is involved in the regulation of cellular signaling by interacting with various signaling pathways, including the PI3K/Akt signaling pathway.

Conclusion

RPL35AP32 is a protein that is expressed in various tissues of the body and is involved in the regulation of mitochondrial dynamics and energy metabolism. Its function is not well understood, but it is thought to play a role in the regulation of neural development, neurotransmission, and cellular signaling. In addition to its role in cellular regulation, RPL35AP32 may also interact with other proteins that are involved in disease progression. Therefore, RPL35AP32 may be a promising target for the development of neuroprotective agents and biomarkers for the diagnosis and treatment of various diseases associated with mitochondrial dysfunction.

Protein Name: Ribosomal Protein L35a Pseudogene 32

The "RPL35AP32 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL35AP32 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets